These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Time-kill study of the activity of telithromycin against macrolide-resistant Streptococcus pneumoniae Isolates with 23S rRNA mutations and changes in ribosomal proteins L4 and L22. Reinert RR; Al-Lahham A Antimicrob Agents Chemother; 2005 Jul; 49(7):3011-3. PubMed ID: 15980387 [TBL] [Abstract][Full Text] [Related]
43. In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations. Farrell DJ; Morrissey I; Bakker S; Buckridge S; Felmingham D Antimicrob Agents Chemother; 2004 Aug; 48(8):3169-71. PubMed ID: 15273142 [TBL] [Abstract][Full Text] [Related]
44. [Molecular analytical evaluation of macrolide- and ketolide-resistant Streptococcus pneumoniae--mechanism of action of telithromycin and resistance to it]. Inoue M; Kaneko K; Nakano R; Sato Y; Arai S Jpn J Antibiot; 2004 Oct; 57(5):425-37. PubMed ID: 15655904 [TBL] [Abstract][Full Text] [Related]
45. Distribution of capsular serotypes and macrolide resistance mechanisms among macrolide-resistant Streptococcus pneumoniae isolates in Korea. Bae S; Lee K Diagn Microbiol Infect Dis; 2009 Feb; 63(2):213-6. PubMed ID: 19097840 [TBL] [Abstract][Full Text] [Related]
46. Molecular basis and clonal nature of increasing pneumococcal macrolide resistance in South Africa, 2000-2005. Wolter N; von Gottberg A; du Plessis M; de Gouveia L; Klugman KP; Int J Antimicrob Agents; 2008 Jul; 32(1):62-7. PubMed ID: 18339522 [TBL] [Abstract][Full Text] [Related]
47. Regional trends in beta-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001-2004. Felmingham D; Cantón R; Jenkins SG J Infect; 2007 Aug; 55(2):111-8. PubMed ID: 17568680 [TBL] [Abstract][Full Text] [Related]
48. Evolution of macrolide resistance in Streptococcus pneumoniae clinical isolates in the prevaccine era. Daikos GL; Koutsolioutsou A; Tsiodras S; Theodoridou M; Koutouzis EI; Charissiadou A; Pangalis A; Michos AG; Chaidopoulou F; Braoudaki M; Syriopoulou VP Diagn Microbiol Infect Dis; 2008 Apr; 60(4):393-8. PubMed ID: 18077121 [TBL] [Abstract][Full Text] [Related]
49. Streptococcus pneumoniae and Streptococcus pyogenes isolated from a paediatric population in Great Britain and Ireland: the in vitro activity of telithromcycin versus comparators. Shackcloth J; Williams L; Farrell DJ J Infect; 2004 Apr; 48(3):229-35. PubMed ID: 15001301 [TBL] [Abstract][Full Text] [Related]
50. Molecular epidemiology of macrolide-resistant Streptococcus pneumoniae isolates in Europe. Reinert RR; Ringelstein A; van der Linden M; Cil MY; Al-Lahham A; Schmitz FJ J Clin Microbiol; 2005 Mar; 43(3):1294-300. PubMed ID: 15750098 [TBL] [Abstract][Full Text] [Related]
51. Activity of telithromycin against erythromycin-susceptible and -resistant Streptococcus pneumoniae isolates from adults with invasive infections. Ortega M; Marco F; Almela M; Puig J; Soriano A; Mensa J Int J Antimicrob Agents; 2004 Dec; 24(6):616-8. PubMed ID: 15555888 [TBL] [Abstract][Full Text] [Related]
52. Antibiotic susceptibility according to genotype of penicillin-binding protein and macrolide resistance genes, and serotype of Streptococcus pneumoniae isolates from community-acquired pneumonia in children. Chiba N; Kobayashi R; Hasegawa K; Morozumi M; Nakayama E; Tajima T; Iwata S; Ubukata K; J Antimicrob Chemother; 2005 Oct; 56(4):756-60. PubMed ID: 16131518 [TBL] [Abstract][Full Text] [Related]
53. Macrolide-resistant Streptococcus pneumoniae in Canada during 1998-1999: prevalence of mef(A) and erm(B) and susceptibilities to ketolides. Hoban DJ; Wierzbowski AK; Nichol K; Zhanel GG Antimicrob Agents Chemother; 2001 Jul; 45(7):2147-50. PubMed ID: 11408241 [TBL] [Abstract][Full Text] [Related]
54. Telithromycin resistance in Streptococcus pneumoniae is conferred by a deletion in the leader sequence of erm(B) that increases rRNA methylation. Wolter N; Smith AM; Farrell DJ; Northwood JB; Douthwaite S; Klugman KP Antimicrob Agents Chemother; 2008 Feb; 52(2):435-40. PubMed ID: 18056269 [TBL] [Abstract][Full Text] [Related]
55. Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan. Hsieh YC; Chang LY; Huang YC; Lin HC; Huang LM; Hsueh PR Clin Microbiol Infect; 2010 Jul; 16(7):973-8. PubMed ID: 19778298 [TBL] [Abstract][Full Text] [Related]
56. Distribution and antibacterial susceptibility of macrolide resistance genotypes in Streptococcus pneumoniae: PROTEKT Year 5 (2003-2004). Farrell DJ; Couturier C; Hryniewicz W Int J Antimicrob Agents; 2008 Mar; 31(3):245-9. PubMed ID: 18178388 [TBL] [Abstract][Full Text] [Related]
57. In vitro activity of telithromycin against respiratory tract pathogens in comparison with other antimicrobial agents. Ling TK; Lee CC Chemotherapy; 2005 Jul; 51(4):182-5. PubMed ID: 15980628 [TBL] [Abstract][Full Text] [Related]
58. Influence of carbon dioxide on the MIC of telithromycin for Streptococcus pneumoniae: an in vitro-in vivo study. Batard E; Juvin ME; Jacqueline C; Bugnon D; Caillon J; Potel G; Drugeon HB Antimicrob Agents Chemother; 2005 Jan; 49(1):464-6. PubMed ID: 15616338 [TBL] [Abstract][Full Text] [Related]
59. Streptococcus pneumoniae isolates resistant to telithromycin. Rantala M; Haanperä-Heikkinen M; Lindgren M; Seppälä H; Huovinen P; Jalava J Antimicrob Agents Chemother; 2006 May; 50(5):1855-8. PubMed ID: 16641460 [TBL] [Abstract][Full Text] [Related]
60. Molecular characterisation of Canadian paediatric multidrug-resistant Streptococcus pneumoniae from 1998-2004. Zhanel GG; Wang X; Nichol K; Nikulin A; Wierzbowski AK; Mulvey M; Hoban DJ Int J Antimicrob Agents; 2006 Nov; 28(5):465-71. PubMed ID: 17049211 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]